Amphastar Pharmaceuticals (AMPH) stock
AMPH's Quality Score rose 1 point on Fri, Nov 20, to 10. It dipped below its 10-day low, then closed back above it.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Key facts on AMPH
| Since its 2023 high | Down 57% |
| Latest filing | 8-K, Nov 5 |
AMPH in the news
AMPH catalysts
After its last 4 reports it closed -9.2% on average, higher 2 of 4 times.
Why AMPH scores 10
Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
- +4Chart checks 4 of 14 firing right now, one point each
- +2Long-term trend above a rising 200-day average, near its 52-week high, down over two years
- Run-up adds
- Profit adds
- Persistence adds
How AMPH ranks in Biotech
AMPH is #28 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 28 |
When does AMPH report earnings, and what happens after?
Expected to report Thu Feb 25, after the close (in 96 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
What AMPH reported on Nov 5, 2026
The quarter
Sales of $207.6M, 8% more than a year ago; a profit of $0.87 a share, from $0.37.
“Changes in net revenues as compared to the third quarter of the prior year were primarily driven by:”
Where the sales came from
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| United States | $191M | $172M | $180M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)
The outlook
No outlook figures read from this release.
In the company's words
“BAQSIMI ® sales increased primarily due to an increase in unit volumes, contributing $7.4 million in sales driven by our continued marketing efforts.”
From its results filing (SEC filing · Nov 5)
The numbers
- $1.2B
- today
- $746M
- up 3.1% on the year
- $139M
- last 12 months
Sales grew 16% a year over 5 years, fiscal 2020 to 2025.
Its share count fell 0.4% a year over 5 years.
Close after the report, last 3
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | +6.4% | +3.0% | +4.4% |
| Aug 6, 2026 | +13.5% | +4.9% | +1.9% |
| May 7, 2026 | -22.7% | -20.9% | -28.0% |
AMPH sales and profit by year
Sales grew in six of the last seven years, to $720M in 2025. It made a profit in seven of the eight years.
AMPH has 4 of 14 chart checks firing
AMPH RSI on Nov 20: 54.2, above its 50-day and 200-day averages
RSI 54.2, MACD below signal, above both averages. Not scored.
The deep dive on AMPH
- What it does and how it makes moneyAnnual report, filed Feb 26, 2026
- Where it stands
- What changed in its filingsSEC filing · Nov 5, 2026SEC filing · Feb 26, 2026, against the one of Mar 3, 2025SEC filing · Feb 26, 2026SEC filing · Nov 5, 2026
- Who holds and trades it
AMPH insider trades
2 insiders sold $477K across 3 filings in the last 6 months. No open-market buys on record. The newest:
AMPH trades by Congress and the executive branch
One trade disclosed in the last six months. The newest:
AMPH's officers and directors
Officers and directors with a Form 4 in the last 12 months.
Which ETFs hold AMPH?
In ETFs: AMPH is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
What Amphastar Pharmaceuticals says it competes with
“We face and will face significant competition for our products and product candidates from pharmaceutical companies that focus on proprietary and generic injectable and inhalation markets such as Pfizer, Inc., BPI Labs, Lupin Pharmaceuticals, Inc., Viatris Inc., Fresenius Kabi USA, Apotex Corp, American Regent Inc., Hikma Pharmaceuticals USA, Inc., Par Pharmaceuticals, Cipla USA Inc., Meitheal Pharmaceuticals, Dr. Reddy’s Laboratories, Inc., Xeris Pharmaceuticals, Medefil Inc., Accord Healthcare, and Teva Pharmaceutical USA Inc. Competition in the generic pharmaceutical industry has increased as producers of branded products have entered the business by creating generic drug subsidiaries, purchasing generic drug companies, or licensing their products to generic manufacturers prior to patent expiration and/or as their patents expire.”
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
Pro members see every line of every stock's score.
- What would move AMPH's score: 5 things
- 2 more filings explained, a plain line each
- Real-time prices, no delay
Straight AnswersStraight Answers
What does AMPH's Quality Score say?
AMPH scores 10 today, which Breakaway calls Average. It is #28 of 273 in Biotech by Quality Score, with 4 of 14 chart checks firing. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
What is AMPH's Quality Score?
AMPH scores 10 today, which Breakaway calls Average (6 to 10). That is #28 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind AMPH's 10.
Are insiders buying AMPH?
2 insiders sold $477K across 3 filings in the last 6 months. No open-market buys on record. The newest is Rong Zhou, Senior EVP, Production Center, who sold $239K on Sep 16. Every filing, with the scored weight, for Pro members.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.